Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

271 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Aberrant Plasma Cell Contamination of Peripheral Blood Stem Cell Autografts, Assessed by Next-Generation Flow Cytometry, Is a Negative Predictor for Deep Response Post Autologous Transplantation in Multiple Myeloma; A Prospective Study in 199 Patients.
Kostopoulos IV, Eleutherakis-Papaiakovou E, Rousakis P, Ntanasis-Stathopoulos I, Panteli C, Orologas-Stavrou N, Kanellias N, Malandrakis P, Liacos CI, Papaioannou NE, Papanota AM, Migkou M, Fotiou D, Gavriatopoulou M, Angelis NV, Kastritis E, Dimopoulos MA, Tsitsilonis OE, Terpos E. Kostopoulos IV, et al. Among authors: gavriatopoulou m. Cancers (Basel). 2021 Aug 11;13(16):4047. doi: 10.3390/cancers13164047. Cancers (Basel). 2021. PMID: 34439201 Free PMC article.
Angiogenesis in Waldenström's macroglobulinemia.
Terpos E, Tasidou A, Kastritis E, Eleftherakis-Papaiakovou E, Gavriatopoulou M, Migkou M, Dimopoulos MA. Terpos E, et al. Among authors: gavriatopoulou m. Clin Lymphoma Myeloma. 2009 Mar;9(1):46-9. doi: 10.3816/CLM.2009.n.011. Clin Lymphoma Myeloma. 2009. PMID: 19362971 Review.
Rituximab-based treatments in Waldenström's macroglobulinemia.
Dimopoulos MA, Kastritis E, Roussou M, Eleutherakis-Papaiakovou E, Migkou M, Gavriatopoulou M, Tassidou A, Terpos E. Dimopoulos MA, et al. Among authors: gavriatopoulou m. Clin Lymphoma Myeloma. 2009 Mar;9(1):59-61. doi: 10.3816/CLM.2009.n.015. Clin Lymphoma Myeloma. 2009. PMID: 19362975 Review.
Dickkopf-1: a suitable target for the management of myeloma bone disease.
Gavriatopoulou M, Dimopoulos MA, Christoulas D, Migkou M, Iakovaki M, Gkotzamanidou M, Terpos E. Gavriatopoulou M, et al. Expert Opin Ther Targets. 2009 Jul;13(7):839-48. doi: 10.1517/14728220903025770. Expert Opin Ther Targets. 2009. PMID: 19530987 Review.
Increased expression of macrophage inflammatory protein-1alpha on trephine biopsies correlates with extensive bone disease, increased angiogenesis and advanced stage in newly diagnosed patients with multiple myeloma.
Roussou M, Tasidou A, Dimopoulos MA, Kastritis E, Migkou M, Christoulas D, Gavriatopoulou M, Zagouri F, Matsouka C, Anagnostou D, Terpos E. Roussou M, et al. Among authors: gavriatopoulou m. Leukemia. 2009 Nov;23(11):2177-81. doi: 10.1038/leu.2009.130. Epub 2009 Jul 9. Leukemia. 2009. PMID: 19587705 No abstract available.
Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors.
Dimopoulos MA, Roussou M, Gavriatopoulou M, Zagouri F, Migkou M, Matsouka C, Barbarousi D, Christoulas D, Primenou E, Grapsa I, Terpos E, Kastritis E. Dimopoulos MA, et al. Among authors: gavriatopoulou m. Clin Lymphoma Myeloma. 2009 Aug;9(4):302-6. doi: 10.3816/CLM.2009.n.059. Clin Lymphoma Myeloma. 2009. PMID: 19717380
High levels of serum TIMP-1 correlate with advanced disease and predict for poor survival in patients with multiple myeloma treated with novel agents.
Terpos E, Dimopoulos MA, Shrivastava V, Leitzel K, Christoulas D, Migkou M, Gavriatopoulou M, Anargyrou K, Hamer P, Kastritis E, Carney W, Lipton A. Terpos E, et al. Among authors: gavriatopoulou m. Leuk Res. 2010 Mar;34(3):399-402. doi: 10.1016/j.leukres.2009.08.035. Epub 2009 Sep 24. Leuk Res. 2010. PMID: 19781774
Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment.
Dimopoulos MA, Christoulas D, Roussou M, Kastritis E, Migkou M, Gavriatopoulou M, Matsouka C, Mparmparoussi D, Psimenou E, Grapsa I, Efstathiou E, Terpos E. Dimopoulos MA, et al. Among authors: gavriatopoulou m. Eur J Haematol. 2010 Jul;85(1):1-5. doi: 10.1111/j.1600-0609.2010.01432.x. Epub 2010 Feb 20. Eur J Haematol. 2010. PMID: 20192988
271 results